Latest insights

The investment landscape is evolving against a backdrop of rising economic uncertainties and a cautious market environment, further complicated by geopolitical tensions and upcoming elections.

Good news! The five-year survival rate for women diagnosed with breast cancer in the United States is now 90%[1]. Unfortunately, when looking at other statistics, the outlook worrying: one in eight women will develop an invasive form of breast cancer during their lifetime. In 2020, two million new cancer cases were diagnosed worldwide. Breast cancer is the most common cancer type among women and the second deadliest, following lung cancer. To better understand the urgency of treatments: in 2020, 685,000 women lost their lives from breast cancer.

And we would rather not have to go through this – which would mean we won the battle and cancer is curable.

The Candriam Institute provides financial support to the PRecISion Medicine Institute. The PRISM technology aims to save an additional 200,000 lives each year by identifying the unique molecular characteristics of each patient's cancer.

The Candriam Institute provides financial support to the PRecISion Medicine Institute. The PRISM technology aims to save an additional 200,000 lives each year by identifying the unique molecular characteristics of each patient's cancer. With this information, more targeted treatment can be applied at each step, improving survival rates.

While cancer is still striking hard and remains among the leading causes of death globally, pharmaceutical innovation is continuing at a high pace. The patients’ survival rate keeps increasing, as is our understanding of the disease and its multiple forms deepens, and as breakthrough therapies are tested and launched. 

Rudi Van Den Eynde, Co-Head of Thematic Global Equity, and Linden Thomson, CFA, Senior Portfolio Manager, explain to investors the approach they used to create and develop an investment strategy in the oncology sector.